Trial intelligence / Profile preview

Phase 2 open-label extension of OPC-67683 in pulmonary multidrug-resistant tuberculosis

2008-005107-26Phase 2Completed

Sponsor
Otsuka Holdings
Start
Feb 2009
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of delamanid in pulmonary tuberculosis (TB), sponsored by Otsuka Holdings. Primary endpoint: Safety and tolerability. Started Feb 2009; status: completed.

02

Drugs

delamanid
03

Conditions

pulmonary tuberculosis (TB)

Beyond the preview

Go deeper on 2008-005107-26.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-005107-26.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call